Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year

Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement